BriaCell Therapeutics (TSX:BCT) recently announced positive survival data from its Phase 2 metastatic breast cancer study. According to the company, patients treated with the Bria-IMT regimen formulation, currently being used in the Phase 3 pivotal trial, experienced a one-year survival rate of 55%. This rate surpasses the survival data of the standard of care for similar patients in this study.
The CEO of BriaCell Therapeutics, William V. Williams, stated that the clinical data supports their belief that the regimen can extend the survival of metastatic breast cancer patients who have not responded to existing treatments. The company is looking forward to confirming these results in the ongoing Phase 3 study, with interim results expected in the second half of 2025. The primary endpoint of the Phase 3 study is overall survival.
The Phase 2 study included 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen and a checkpoint inhibitor. Out of these patients, 37 were treated with the formulation used in the Phase 3 study. The final median overall survival calculation is pending as many patients are still alive.
BriaCell Therapeutics is a clinical-stage biotechnology company headquartered in Vancouver, focused on developing innovative immunotherapies for cancer treatment. The company’s shares are up 2.70% to C$1.14 as of 10:19 am ET.
The ongoing Phase 3 study aims to enroll up to 354 patients, with completion expected by mid-2025. The study will compare overall survival with the Bria-IMT regimen plus checkpoint inhibitor versus a physician’s choice treatment.
Investors interested in discussing this development can visit the BriaCell Therapeutics Bullboard investor discussion forum. Please note that the information provided is for informational purposes only and should not be considered investment advice. For full disclaimer information, please refer to the designated link.
Image source: Shutterstock
